Theravance Biopharma Inc.

NASDAQ: TBPH · Real-Time Price · USD
13.03
0.09 (0.70%)
At close: Aug 15, 2025, 1:14 PM

Theravance Biopharma Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
64.38M 57.42M 51.35M 55.31M
Cost of Revenue
n/a n/a 6.59M 7.29M
Gross Profit
64.38M 57.42M 44.76M 48.02M
Operating Income
-46.95M -56.03M -91.96M -257.78M
Interest Income
4.88M 9.12M 8.54M 1.11M
Pretax Income
-44.61M -49.27M -92.81M -199.58M
Net Income
-56.42M -55.19M -92.82M -199.43M
Selling & General & Admin
69.17M 70.09M 67.07M 99.3M
Research & Development
37.64M 40.62M 63.39M 193.66M
Other Expenses
4.51M 2.74M n/a n/a
Operating Expenses
111.33M 113.46M 130.47M 292.95M
Interest Expense
2.55M 2.35M 6.37M 8.55M
Selling & Marketing Expenses
n/a n/a 8M n/a
Cost & Expenses
111.33M 113.46M 130.47M 292.95M
Income Tax Expense
11.8M 5.92M 9K -151K
Shares Outstanding (Basic)
48.85M 55.3M 73.59M 69.46M
Shares Outstanding (Diluted)
48.85M 55.3M 73.59M 69.46M
EPS (Basic)
-1.15 -1 -1.26 -2.87
EPS (Diluted)
-1.15 -1 -1.26 -2.87
EBITDA
-38.45M -42.66M -79.86M -249.39M
EBIT
-42.07M -46.92M -86.45M -256.68M
Depreciation & Amortization
3.62M 4.26M 6.59M 7.29M